159 related articles for article (PubMed ID: 14657011)
1. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
Agostini M; Gurnell M; Savage DB; Wood EM; Smith AG; Rajanayagam O; Garnes KT; Levinson SH; Xu HE; Schwabe JW; Willson TM; O'Rahilly S; Chatterjee VK
Endocrinology; 2004 Apr; 145(4):1527-38. PubMed ID: 14657011
[TBL] [Abstract][Full Text] [Related]
2. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.
Gurnell M; Wentworth JM; Agostini M; Adams M; Collingwood TN; Provenzano C; Browne PO; Rajanayagam O; Burris TP; Schwabe JW; Lazar MA; Chatterjee VK
J Biol Chem; 2000 Feb; 275(8):5754-9. PubMed ID: 10681562
[TBL] [Abstract][Full Text] [Related]
3. Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity.
Stanley TB; Leesnitzer LM; Montana VG; Galardi CM; Lambert MH; Holt JA; Xu HE; Moore LB; Blanchard SG; Stimmel JB
Biochemistry; 2003 Aug; 42(31):9278-87. PubMed ID: 12899614
[TBL] [Abstract][Full Text] [Related]
4. Resistance to thyroid hormone, and peroxisome-proliferator-activated receptor gamma resistance.
Chatterjee VK
Biochem Soc Trans; 2001 May; 29(Pt 2):227-31. PubMed ID: 11356159
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation.
Nugent C; Prins JB; Whitehead JP; Savage D; Wentworth JM; Chatterjee VK; O'Rahilly S
Mol Endocrinol; 2001 Oct; 15(10):1729-38. PubMed ID: 11579205
[TBL] [Abstract][Full Text] [Related]
6. A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth.
Bruemmer D; Berger JP; Liu J; Kintscher U; Wakino S; Fleck E; Moller DE; Law RE
Eur J Pharmacol; 2003 Apr; 466(3):225-34. PubMed ID: 12694805
[TBL] [Abstract][Full Text] [Related]
7. T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities.
Lee G; Elwood F; McNally J; Weiszmann J; Lindstrom M; Amaral K; Nakamura M; Miao S; Cao P; Learned RM; Chen JL; Li Y
J Biol Chem; 2002 May; 277(22):19649-57. PubMed ID: 11877444
[TBL] [Abstract][Full Text] [Related]
8. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
Cobb JE; Blanchard SG; Boswell EG; Brown KK; Charifson PS; Cooper JP; Collins JL; Dezube M; Henke BR; Hull-Ryde EA; Lake DH; Lenhard JM; Oliver W; Oplinger J; Pentti M; Parks DJ; Plunket KD; Tong WQ
J Med Chem; 1998 Dec; 41(25):5055-69. PubMed ID: 9836622
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.
Li AC; Brown KK; Silvestre MJ; Willson TM; Palinski W; Glass CK
J Clin Invest; 2000 Aug; 106(4):523-31. PubMed ID: 10953027
[TBL] [Abstract][Full Text] [Related]
10. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.
Barroso I; Gurnell M; Crowley VE; Agostini M; Schwabe JW; Soos MA; Maslen GL; Williams TD; Lewis H; Schafer AJ; Chatterjee VK; O'Rahilly S
Nature; 1999 Dec 23-30; 402(6764):880-3. PubMed ID: 10622252
[TBL] [Abstract][Full Text] [Related]
11. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Henke BR; Blanchard SG; Brackeen MF; Brown KK; Cobb JE; Collins JL; Harrington WW; Hashim MA; Hull-Ryde EA; Kaldor I; Kliewer SA; Lake DH; Leesnitzer LM; Lehmann JM; Lenhard JM; Orband-Miller LA; Miller JF; Mook RA; Noble SA; Oliver W; Parks DJ; Plunket KD; Szewczyk JR; Willson TM
J Med Chem; 1998 Dec; 41(25):5020-36. PubMed ID: 9836620
[TBL] [Abstract][Full Text] [Related]
12. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.
Savage DB; Tan GD; Acerini CL; Jebb SA; Agostini M; Gurnell M; Williams RL; Umpleby AM; Thomas EL; Bell JD; Dixon AK; Dunne F; Boiani R; Cinti S; Vidal-Puig A; Karpe F; Chatterjee VK; O'Rahilly S
Diabetes; 2003 Apr; 52(4):910-7. PubMed ID: 12663460
[TBL] [Abstract][Full Text] [Related]
13. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators.
Fujimura T; Sakuma H; Konishi S; Oe T; Hosogai N; Kimura C; Aramori I; Mutoh S
J Pharmacol Sci; 2005 Dec; 99(4):342-52. PubMed ID: 16314690
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene.
Li M; Pascual G; Glass CK
Mol Cell Biol; 2000 Jul; 20(13):4699-707. PubMed ID: 10848596
[TBL] [Abstract][Full Text] [Related]
15. A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.
Tagami T; Yamamoto H; Moriyama K; Sawai K; Usui T; Shimatsu A; Naruse M
Endocrinology; 2009 Feb; 150(2):862-70. PubMed ID: 19147680
[TBL] [Abstract][Full Text] [Related]
16. Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer.
Zhou G; Cummings R; Li Y; Mitra S; Wilkinson HA; Elbrecht A; Hermes JD; Schaeffer JM; Smith RG; Moller DE
Mol Endocrinol; 1998 Oct; 12(10):1594-604. PubMed ID: 9773982
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.
Bruemmer D; Yin F; Liu J; Berger JP; Sakai T; Blaschke F; Fleck E; Van Herle AJ; Forman BM; Law RE
Circ Res; 2003 Aug; 93(4):e38-47. PubMed ID: 12881480
[TBL] [Abstract][Full Text] [Related]
18. A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells.
Park Y; Freedman BD; Lee EJ; Park S; Jameson JL
Diabetologia; 2003 Mar; 46(3):365-77. PubMed ID: 12687335
[TBL] [Abstract][Full Text] [Related]
19. Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists.
Davies SS; Pontsler AV; Marathe GK; Harrison KA; Murphy RC; Hinshaw JC; Prestwich GD; Hilaire AS; Prescott SM; Zimmerman GA; McIntyre TM
J Biol Chem; 2001 May; 276(19):16015-23. PubMed ID: 11279149
[TBL] [Abstract][Full Text] [Related]
20. PPARgamma agonists enhance human vascular endothelial adhesiveness by increasing ICAM-1 expression.
Chen NG; Sarabia SF; Malloy PJ; Zhao XY; Feldman D; Reaven GM
Biochem Biophys Res Commun; 1999 Oct; 263(3):718-22. PubMed ID: 10512746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
